Current mood: A good thesis is a finished thesis. A good thesis is a finished thesis. A good thesis is a finished thesis. A good thesis is a finished thesis. … Academic Chatter™

Hi, i'm seeking an experienced senior project manager to help deliver the Luminese Alliance Data Enabling Platform, an ambitious initiative in precision medicine, data linkage and real-time clinical data extraction. Luminesce Alliance linkedin.com/jobs/view/3684…

EVERY child diagnosed with cancer in Australia now has access to precision medicine through our world-leading ZERO Childhood Cancer Program. Childrens Cancer Institute continues to push the boundaries of what's possible through research and offers real hope for a brighter future.

Do enough people know about the glory of scales::label_wrap???? (No)

Save the date! Have you heard the we are running a cancer bioinformatics symposium in June? Registration and abstract submission are opening soon! cancerbioinformatics.au

cat is the most misused thing by programmers new to linux. I cringe every time someone uses it wrong in a bash script. Thread below with proper uses of cat only

We’re happy to share our preprint on evidence yield from genome sequencing for the calibrated PP3/BP4 computational recommendations, where we find a median of 1 rare missense variant reaching PP3 “Strong” evidence per person in disease-associated genes. 1/ medrxiv.org/content/10.110…

I am currently recruiting a computational postdoc in my lab at CU dashnowlab.org The candidate would develop and use computational genomics methods to understand the genetic underpinnings of rare diseases and increase diagnoses. Pay starts at $70k for recent PhD grads

Brb updating my LinkedIn to “Endorsed by Bioinformatics Royalty”

How to choose the right chart for analysis:

Published today Springer Nature in Nature Methods Genomics 2 Proteins portal G2P: a resource and discovery tool for linking genetic screening outputs to protein sequences and structures nature.com/articles/s4159… /thread

David Cheerie and I will present at the first N1 Collaborative annual meeting tomorrow! We will discuss the newly established N1C VARIANT (Variant Assessments towards Eligibility for Antisense Oligonucleotide Treatment) Guidelines. medrxiv.org/content/10.110…